United States  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

$5.1B deal: GSK to buy Boston-area cancer drug developer

bizjournals Monday, 3 December 2018
In a major move to boost its oncology product pipeline, GlaxoSmithKline entered into a definitive agreement Monday to acquire Boston-area biopharmaceutical company Tesaro for $5.1 billion. Tesaro (NASDAQ: TSRO) of Waltham, Mass., markets the ovarian cancer therapy Zejula, which is approved in the United States and Europe. The company is also conducting clinical trials that if successful could lead to an expanded use of the drug, as a monotherapy and in combination with other ovarian cancer treatments. Hal…
0
shares
ShareTweetSavePostSend
 
Credit: CBS2 LA - Published < > Embed
News video: ONLY ON 2: Diabetes Drug That Kills Cancer?

ONLY ON 2: Diabetes Drug That Kills Cancer? 03:12

It's a kinder, far gentler approach to killing cancer. A Long Beach oncologist is reporting a near miracle. A young woman with stage 4 cancer got better after taking an inexpensive drug used by millions of Americans. Sharon Tay reports.

Recent related videos from verified sources

Prostate Cancer Drug Leads To Increased Risk Of Another Dangerous Condition [Video]Prostate Cancer Drug Leads To Increased Risk Of Another Dangerous Condition

A new study reveals a common prostate cancer drug has been linked to type 2 diabetes. According to UPI, researchers from the University of Edinburgh found that men taking 5-alpha-reductase inhibitors..

Credit: Wochit News     Duration: 00:41Published

Doctors To Be Required To Address Breast Density In Mammogram Results [Video]Doctors To Be Required To Address Breast Density In Mammogram Results

Doctors across the U.S. may soon be required to provide women with more information about their mammography results. This week, the Food and Drug Administration announced plans to update a rule that..

Credit: Wochit News     Duration: 00:40Published

KU Cancer Center patient grateful for immunotherapy drug [Video]KU Cancer Center patient grateful for immunotherapy drug

KU Cancer Center patient grateful for immunotherapy drug

Credit: 41 Action News     Duration: 03:10Published


Recent related news from verified sources

Orgenesis strikes deal with Columbia University to develop Cellular Vaccination product platform

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, has struck a deal with Columbia University under which it will fund research to develop a...
Proactive Investors

Moleculin stages cancer trials in Poland

Moleculin Biotech Inc (NASDAQ:MBRX), the US biopharmaceutical group, announced Thursday that it will bolster its trials in the US for its anti-cancer drugs by...
Proactive Investors

You Might Like


Other recent news in Business

2 major European mergers just collapsed — DEUTSCHE BANK-Commerzbank talks flopped and Walmart's $9 billion UK supermarket deal was blockedTesla posted one of its worst quarters in years, but one analyst says there's still a way ELON MUSK can get the company back on track (TSLA)
The $5 BILLION FINE Facebook expects to pay the FTC is a joke — on all of us (FB)'Avengers: ENDGAME' marks a new beginning for Disney stock
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.